Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 28Lymphoma 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Breast Neoplasms 22Multiple Myeloma 21Lymphoma, Large B-Cell, Diffuse 21Carcinoma, Non-Small-Cell Lung 21Lymphoma, Non-Hodgkin 19Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hodgkin Disease 15Lymphoma, T-Cell, Cutaneous 13Glioblastoma 13Leukemia, Lymphocytic, Chronic, B-Cell 12Brain Neoplasms 12Recurrence 11Neuroblastoma 11Myelodysplastic Syndromes 11Mycosis Fungoides 11Lymphoma, B-Cell, Marginal Zone 11Leukemia 11Burkitt Lymphoma 11Neoplasms 10Sezary Syndrome 9Congenital Abnormalities 9Prostatic Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Squamous Cell Carcinoma of Head and Neck 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms, Plasma Cell 7

Interventions

Cisplatin 41Gemcitabine 25Radiotherapy, Intensity-Modulated 15Fluorouracil 15Radiotherapy 12Docetaxel 10pembrolizumab 8Paclitaxel 8Carboplatin 8Capecitabine 7Oxaliplatin 5toripalimab 4spartalizumab 4Surveys and Questionnaires 4Bevacizumab 4camrelizumab 3Nivolumab 3Induction Chemotherapy 3Immunohistochemistry 3Endostatins 3Counseling 3Cetuximab 3Acupuncture Therapy 3tislelizumab 2sintilimab 2nimotuzumab 2endostar protein 2apatinib 2Taxes 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Neoplasms × Vorinostat × Clear all
NCT02538510 2024-11-26

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

University of Washington

Phase 1/2 Completed
50 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡